FULL SUPPLEMENT: THE ROLE OF EPIDERMAL BARRIER DYSFUNCTION AND CUTANEOUS MICROBIOME DYSBIOSIS IN THE PATHOGENESIS AND MANAGEMENT OF ACNE VULGARIS AND ROSACEA

September 2022 | Volume 21 | Issue 9 | SF3502911 | Copyright © September 2022


Published online August 31, 2022

Abstract
Appropriately developed prescription and OTC preparations may selectively influence the microbiome and potentially maintain/restore EBF. By understanding this relationship, dermatologists will be better able to educate patients on the importance of appropriate skin care.
In this supplement:

Dysbiosis, (Barrier) Dysfunction, and Dermatoses: A Chicken-and-Egg Dilemma
Acne vulgaris (AV) and rosacea are two of the most common dermatoses diagnosed and managed by dermatologists.1,2 Despite this and our improved understanding of the unique pathogenesis of each, there has been little focus on general skin care and how it may affect physiologic functioning of the epidermis until recently.

Read the article here.

The Role of Epidermal Barrier Dysfunction and Cutaneous Microbiome
Dysbiosis in the Pathogenesis and Management of Acne Vulgaris and Rosacea Dysregulation of either the cutaneous microbiome (CM) or epidermal barrier function (EBF) is thought to play an increasingly important role in acne vulgaris (AV) and rosacea pathogenesis.

Read the article here.